# SciBrunch Therapeutics

Source: https://onco.cc/companies/scibrunch-therapeutics/  
OnCo record `scibrunch-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

SciBrunch Therapeutics is a Shanghai company founded in late 2024 that makes pills for hard-to-treat cancers such as pancreatic and bowel cancer. In September 2026 MSD licensed its KRAS G12D drug, a molecular glue not yet tested in people, for USD 400 million upfront; its PARP1 blocker began its first human trial in January 2026.

## Summary

SciBrunch Therapeutics, headquartered in Pudong, Shanghai, was founded in late 2024 by serial entrepreneur Tao Hu (chairman and chief executive) and medicinal chemist Yang Zhang (chief scientific officer), with a focus on malignancies such as pancreatic ductal adenocarcinoma and colorectal cancer. Its pipeline comprises SPR1020, a brain-penetrant, highly selective PARP1 inhibitor whose phase 1/2 first-in-human study dosed its first patient on 8 January 2026, for breast, ovarian and prostate cancer and glioma; SPR2015, a molecular glue inhibitor of active (ON-state) KRAS G12D for pancreatic, lung and colorectal cancer; and a KRAS G12V (ON) molecular glue in discovery. On 28 September 2026 it granted MSD (Merck & Co.) an exclusive global licence to SPR2015 for USD 400 million upfront, with total potential value including milestones of USD 2.13 billion. The company raised an angel round of over RMB 200 million in June 2025, co-led by BioTrack Capital and Hankang Capital, and a pre-A round of over USD 35 million in January 2026 led by HighLight Capital.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: Shanghai SciBrunch Therapeutics
- HQ: Shanghai
- Type: biotech
- Website: https://www.scibrunch.com/

## Notes

- Founded in late 2024 per the company's September 2026 licence release; the exact month is not stated. The company headline that the two rounds total USD 65 million mixes an RMB and a USD figure and is not repeated. None of the investors has an investor record in the corpus. Trade coverage reported that SPR2015 is expected to enter human trials by the end of 2026; the company release read does not give a date.

## Sources

- Official website: https://www.scibrunch.com/
- MSD licence for SPR2015, September 2026: https://www.scibrunch.com/news/6
- Pre-A financing, January 2026: https://www.scibrunch.com/news/4
- Angel financing, June 2025: https://www.scibrunch.com/news/1
- BioSpace: Merck deal with SciBrunch: https://www.biospace.com/deals/merck-inks-up-to-2-13b-deal-to-dine-with-scibrunch-gain-rights-to-preclinical-kras-inhibitor

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [KRAS & RAS inhibitors](https://onco.cc/technologies/kras-inhibitors/), [Molecular glue discovery platforms](https://onco.cc/technologies/molecular-glue-platforms/), [PARP inhibitors](https://onco.cc/technologies/parp-inhibitor/)
- targets: [KRAS](https://onco.cc/targets/kras/), [PARP](https://onco.cc/targets/parp/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)
- trials: [An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct07359066/)

---
JSON: https://onco.cc/api/v1/entities/scibrunch-therapeutics.json